Amgen’s experimental bone drug denosumab took another small step toward the market yesterday, as the company said the drug outperformed Merck’s Fosamax in a head-to-head trial.
Amgen tested the drug on post-menopausal women with low bone mineral density (the standard test for bone strength) who were already taking Fosamax. Half of the women were switched to [...]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment